Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 1.00 |
| ▸ | CTSB | P07858 | 5/20 | 0.80 |
| ▸ | CTSL | P07711 | 5/20 | 0.80 |
| ▸ | CTSS | P25774 | 3/20 | 0.80 |
| ▸ | CTSF | Q9UBX1 | 3/20 | 0.80 |
| ▸ | CTSV | O60911 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Odanacatib SCHEMBL18540595 | 0.89 | CTSK (1.00) | CTSKCTSBCTSLCTSSCTSF | |
| Odanacatib SCHEMBL3479347 | 0.89 | CTSK (1.00) | CTSKCTSBCTSLCTSSCTSF | |
| Odanacatib SCHEMBL1496266 | 0.89 | CTSK (1.00) | CTSKCTSBCTSLCTSSCTSF | |
| Odanacatib SCHEMBL15827397 | 0.89 | CTSK (1.00) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL2154985 | 0.87 | CTSK (1.00) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL2155279 | 0.87 | CTSK (0.88) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL3682967 | 0.87 | CTSK (0.78) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL5183859 | 0.85 | CTSK (0.74) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL13446020 | 0.84 | CTSK (0.82) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL2155573 | 0.84 | CTSK (0.90) | CTSKCTSBCTSLCTSSCTSF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150250759-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | MERCK SHARP & DOHME CORP. (US) | 2015-09-10 | — | — | US | claimed |
| EP-2783687-A1 | Composition for inhibition of cathepsin K | Merck Sharp & Dohme Corp. (US) | 2014-10-01 | — | — | EP | claimed |
| US-20140186471-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | MERCK SHARP & DOHME (US) | 2014-07-03 | — | — | US | claimed |
| US-20090005323-A1 | Cathepsin K Inhibitors and Obesity | MERCK FROSST CANADA LTD. (CA) | 2009-01-01 | — | — | US | claimed |
| US-20080255072-A1 | Oral unit dose for inhibiting bone resorption; reduced frequency regime; N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; blister pack card orienting the dosages in the order of their intended use | MERCK SHARP & DOHME LLC | 2008-10-16 | — | — | US | claimed |
| US-20080125442-A1 | Cathepsin K Inhibitors and Atherosclerosis | MERCK FROSST CANADA LTD. (CA) | 2008-05-29 | — | — | US | claimed |
| US-20150250759-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | MERCK SHARP & DOHME CORP. (US) | 2015-09-10 | — | — | US | disclosed |
| EP-2783687-A1 | Composition for inhibition of cathepsin K | Merck Sharp & Dohme Corp. (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20140186471-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | MERCK SHARP & DOHME (US) | 2014-07-03 | — | — | US | disclosed |
| US-8722734-B2 | Composition for inhibition of cathepsin K | MERCK SHARP & DOHME CORP. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20090005323-A1 | Cathepsin K Inhibitors and Obesity | MERCK FROSST CANADA LTD. (CA) | 2009-01-01 | — | — | US | disclosed |
| US-20080255072-A1 | Oral unit dose for inhibiting bone resorption; reduced frequency regime; N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; blister pack card orienting the dosages in the order of their intended use | MERCK SHARP & DOHME LLC | 2008-10-16 | — | — | US | disclosed |
| US-20080125442-A1 | Cathepsin K Inhibitors and Atherosclerosis | MERCK FROSST CANADA LTD. (CA) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125442-A1 | Cathepsin K Inhibitors and Atherosclerosis | CTSK, CTSD, CTSS | CTSK 1/4885CTSB 5/4885CTSL 11/4885 |
| US-20090005323-A1 | Cathepsin K Inhibitors and Obesity | CTSK, CTSG, CTSB | CTSK 1/4885CTSB 3/4885CTSL 13/4885 |
| US-20140186471-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | CTSK, CTSB, CTSZ | CTSK 1/4885CTSB 2/4885CTSL 12/4885 |
| US-20080255072-A1 | Oral unit dose for inhibiting bone resorption; reduced frequency regime; N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; blister pack card orienting the dosages in the order of their intended use | CTSK, CTSB, CTSE | CTSK 1/4885CTSB 2/4885CTSL 7/4885 |
| US-20150250759-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | CTSK, CTSB, CTSZ | CTSK 1/4885CTSB 2/4885CTSL 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.